PROM1 and cancer: It’s true and clear that CD133-positive, compared to the counterpart CD133-negative, endows with the features, the preferential capacities of cancer cell and stem cell, of increased ability to promote tumorigenicity and metastasis in vitro and in vivo, as well as the ability to differentiate into varied lineages.